Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11494450 | 0.89 | CYP2C9 (0.50) | KMT2AMAPTCYP2C19HIF1AKIF11 | |
| SCHEMBL3291465 | 0.85 | CYP2C19 (0.69) | KMT2AMAPTCYP2C19HIF1ANR3C2 | |
| SCHEMBL25332888 | 0.85 | CYP2C19 (0.69) | KMT2AMAPTCYP2C19HIF1ANR3C2 | |
| SCHEMBL1202058 | 0.85 | CYP2C19 (0.69) | KMT2AMAPTCYP2C19HIF1ANR3C2 | |
| SCHEMBL11506731 | 0.85 | PARP10 (0.49) | KMT2ALMNA | |
| SCHEMBL30944447 | 0.83 | CYP2C19 (0.55) | KMT2AMAPTCYP2C19HIF1ANR3C2 | |
| SCHEMBL2813766 | 0.82 | MAPT (0.55) | KMT2AMAPTCYP2C19HIF1ATAAR1 | |
| SCHEMBL362442 | 0.82 | KMT2A (0.55) | KMT2AMAPTCYP2C19HIF1ATAAR1 | |
| Hydrochloric Acid SCHEMBL5789392 | 0.80 | MAPT (0.53) | KMT2AMAPTCYP2C19HIF1ATAAR1 | |
| SCHEMBL10483830 | 0.79 | MAPT (0.47) | KMT2AMAPTCYP2C19HIF1AKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | claimed |
| EP-1363906-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | claimed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | claimed |
| WO-2008118457-A2 | SYNTHESIS OF RESOLVINS AND INTERMEDIATES, COMPOUNDS PREPARED THEREBY, AND USES THEREOF | UNIVERSITY OF MEDICINE AND DENTISTRY OF NJ (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1718632-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2006-11-08 | — | — | EP | disclosed |
| US-20060046966-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| US-6995142-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1329457-B1 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMA (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005075458-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTORS ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-08-18 | — | — | WO | disclosed |
| US-6906198-B1 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040072907-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | PETER DRAGOVICH S (US) | 2004-04-15 | — | — | US | disclosed |
| US-6649639-B2 | Inhibit or block the biological activity of the picornaviral 3C protease. | DRAGOVICH PETER S (US) | 2003-11-18 | — | — | US | disclosed |
| EP-0975588-B1 | ANTIPICORNAVIRAL COMPOUDS, COMPOSITIONS CONTAINING THEM, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2003-09-03 | — | — | EP | disclosed |
| EP-1329457-A2 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMACEUTICALS, INC. (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030130204-A1 | Antipicornaviral compounds and compositons, their pharmaceutical uses, and materials for their synthesis | DRAGOVICH PETER SCOTT (US) | 2003-07-10 | — | — | US | disclosed |
| US-6531452-B1 | Peptide-like and peptidomimetic compounds that inhibit enzymatic activity of picornaviral 3C proteases and inhibit picornavirus replication | AGOURON PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | DRAGOVICH PETER S (US) | 2002-03-14 | — | — | US | disclosed |
| US-6331554-B1 | PICORNAVIRUS PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| US-6020371-A | VIRICIDES; PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2000-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043037-A1 | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | KMT2A 1620/4885MAPT 1214/4885CYP2C19 1021/4885 |
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | RNASEL, RNASE1, GTF3C3 | KMT2A 3212/4885MAPT 1709/4885CYP2C19 3226/4885 |
| US-20040072907-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | PCNA, ZC3HAV1, POLR1C | KMT2A 4120/4885MAPT 3665/4885CYP2C19 4876/4885 |
| US-20060046966-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SARNP | KMT2A 4069/4885MAPT 2481/4885CYP2C19 2405/4885 |
| US-20030130204-A1 | Antipicornaviral compounds and compositons, their pharmaceutical uses, and materials for their synthesis | SARNP, RNASE1, SERPINA3 | KMT2A 4547/4885MAPT 1685/4885CYP2C19 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.